1. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice

2. Program

3. The Impact of Treatment Success and Flares in Patients With Psoriasis

4. Learning Objectives

5. Psoriasis Is Common

6. Global Prevalence of Psoriasis

7. Psoriasis Is Impactful

8. Symptoms Are Bothersome Every Day

9. Psoriasis Is Impactful

10. Skindex 29 Results in 936 Patients with Psoriasis

11. Clear About Psoriasis Survey -- Discrimination and Humiliation

12. QoL: Itch and Location of Disease Is Important

13. Modern Treatment Improves QoL

14. AMAGINE 1,2,3: Relationship of DLQI (0,1) and PASI Score at Weeks 12 and 52 With Brodalumab

15. Percentage of Patients With DLQI = 0 by PASI Response at Week 12 With Adalimumab

16. New Goals of Therapy

17. Case Presentation

18. Case Presentation (cont)

19. Case Presentation (cont)

20. Case Presentation (cont)

21. What Happens When Patients Achieve Clear Skin but Then Flare?

22. What Happens When Patients Achieve Clear Skin but Then Flare? (cont)

23. What Happens When Patients Achieve Clear Skin but Then Flare? (cont)

24. Impact of Treatment Success and Flares

25. Achieving and Maintaining Stable Remission in Clinical Practice

26. Psoriasis Is Significant

27. PsA Is Significant

28. The Comorbidity Spectrum of Psoriasis/PsA Is Significant

29. Psoriasis and Risk for Myocardial Infarction

30. Independent CV Risk in Psoriasis

31. Increased CV Risk Due to Psoriasis

32. Cumulative Life Course Impairment in Psoriasis

33. Is This Healthy?

34. VIP-U: Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Ustekinumab for Psoriasis on Aortic Vascular Inflammation

35. VIP-U: Baseline Demographics, Psoriasis Outcomes, and 18FDG PET/CT Total Aortic Vascular Inflammation at Week 12

36. CARIMA: FMD Results

37. Skin Disease Severity and Clinical Reduction of Skin Disease Severity Is Linked With CV Risk in Psoriasis

38. Guselkumab Demonstrates Greater Reductions in Anxiety and Depression Symptoms Than Adalimumab in Psoriasis Patients

39. Treatment Goals as per Patient Benefit Index (cont)

40. UNCOVER-2 and -3: Association of HRQoL With Skin Outcomes and PASI Improvement

41. Relationship Between Patient-Reported Impact of Psoriasis and Absolute PASI Outcomes (ERASURE/FIXTURE)

42. Efficacy Outcomes Comparison Ixekizumab vs Ustekinumab Week 24, NRI

43. Network Meta-Analysis: The Comparative Efficacy for Novel Treatments of Moderate to Severe Plaque Psoriasis

44. Treatment Goals as per Patient Benefit Index (cont)

45. Significantly More Patients Treated With IXE vs ETN and PBO Achieved PASI 75 as Early as Weeks 1 and 2

46. Treatment Goals as per Patient Benefit Index (cont)

47. VOYAGE 1 Guselkumab vs Adalimumab: PSSD Symptoms Score = 0*

48. Patient Treatment Goals Change With Therapy and in Subgroups

49. BIOBADADERM Registry: Kaplan-Meier Survival Estimates for all Causes of Discontinuation and Lack of Efficacy

50. Durability of Response in PHOENIX 2 Long-Term Response to Ustekinumab Through Week 244

51. High Levels of Skin Clearance Are Associated With Improved Quality of Life

52. New Treatment Goals in Psoriasis

53. Absolute PASI Responses Over 3 Years With Ixekizumab ITT Population# - UNCOVER-3

54. Achieving and Maintaining Stable Remission in Clinical Practice

55. Potential Topics for Discussion (will also include audience Q&A)

56. Abbreviations

57. Abbreviations (cont)

58. Abbreviations (cont)

59. Abbreviations (cont)